145 related articles for article (PubMed ID: 37783903)
1. Enhancing PSMA PET/CT imaging of prostate cancer: investigating the impact of multiple time point evaluation, diuretic administration, cribriform pattern, and intraductal carcinoma.
Guner LA; Unal K; Beylergil V; Tuna MB; Saglican Y; Vardareli E; Kural AR
Ann Nucl Med; 2023 Nov; 37(11):618-628. PubMed ID: 37783903
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Findings in 1,123 Men with Preoperative
Raveenthiran S; Yaxley WJ; Franklin T; Coughlin G; Roberts M; Gianduzzo T; Kua B; Samaratunga H; Delahunt B; Egevad L; Wong D; McEwan L; Brown N; Parkinson R; Esler R; Yaxley JW
J Urol; 2022 Mar; 207(3):573-580. PubMed ID: 34694140
[TBL] [Abstract][Full Text] [Related]
4.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
5. Detection and localisation of primary prostate cancer using
Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M
BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
[TBL] [Abstract][Full Text] [Related]
6. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
7. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of
Gao J; Zhang C; Zhang Q; Fu Y; Zhao X; Chen M; Zhang B; Li D; Shi J; Wang F; Guo H
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1531-1541. PubMed ID: 31025048
[TBL] [Abstract][Full Text] [Related]
9. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
[TBL] [Abstract][Full Text] [Related]
10.
Esen T; Falay O; Tarim K; Armutlu A; Koseoglu E; Kilic M; Seymen H; Sarikaya AF; Kiremit MC; Balbay MD; Canda AE; Baydar DE; Kordan Y; Demirkol MO; Tilki D
Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
[TBL] [Abstract][Full Text] [Related]
11. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
12. Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection.
Dekalo S; Kuten J; Mintz I; Fahoum I; Gitstein G; Keizman D; Sarid D; Matzkin H; Mabjeesh NJ; Beri A; Even-Sapir E; Yossepowitch O; Mano R
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):910-916. PubMed ID: 33790418
[TBL] [Abstract][Full Text] [Related]
13. Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses.
Aksu A; Vural Topuz Ö; Yılmaz G; Çapa Kaya G; Yılmaz B
Ann Nucl Med; 2022 Mar; 36(3):310-318. PubMed ID: 34988888
[TBL] [Abstract][Full Text] [Related]
14. A Multicenter Prospective Clinical Trial of
McCarthy M; Francis R; Tang C; Watts J; Campbell A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
[TBL] [Abstract][Full Text] [Related]
15. The role of (
Yilmaz U; Komek H; Can C; Altindag S
Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
[TBL] [Abstract][Full Text] [Related]
16. Head-to-Head Comparison of
Sonni I; Felker ER; Lenis AT; Sisk AE; Bahri S; Allen-Auerbach M; Armstrong WR; Suvannarerg V; Tubtawee T; Grogan T; Elashoff D; Eiber M; Raman SS; Czernin J; Reiter RE; Calais J
J Nucl Med; 2022 Jun; 63(6):847-854. PubMed ID: 34649942
[TBL] [Abstract][Full Text] [Related]
17. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
Kulkarni SC; Sundaram PS; Padma S
Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366
[TBL] [Abstract][Full Text] [Related]
18. Comparison of
Schollhammer R; Robert G; Asselineau J; Yacoub M; Vimont D; Balamoutoff N; Bladou F; Bénard A; Hindié E; Gallerande HC; Morgat C
J Nucl Med; 2023 Mar; 64(3):379-385. PubMed ID: 36215569
[TBL] [Abstract][Full Text] [Related]
19. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
20. Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.
Park SY; Zacharias C; Harrison C; Fan RE; Kunder C; Hatami N; Giesel F; Ghanouni P; Daniel B; Loening AM; Sonn GA; Iagaru A
Radiology; 2018 Aug; 288(2):495-505. PubMed ID: 29786490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
